Disruption of p16 and Activation of Kras in Pancreas Increase Ductal Adenocarcinoma Formation and Metastasis in vivo

Thun, 2009, Cancer statistics, 2009, CA Cancer J Clin, 59, 225, 10.3322/caac.20006

Tempero, 2001, A white paper: the product of a pancreas cancer think tank, Cancer Res, 61, 4923

Perucho, 1988, Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes, Cell, 53, 549, 10.1016/0092-8674(88)90571-5

Bos, 1988, KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas, Nucleic Acids Res, 16, 7773, 10.1093/nar/16.16.7773

Kern, 2000, Genetic progression in the pancreatic ducts, Am J Pathol, 156, 1821, 10.1016/S0002-9440(10)65054-7

Barbacid, 2003, Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context, Cancer Cell, 4, 111, 10.1016/S1535-6108(03)00191-0

Devereux, 2001, Wildtype Kras2 can inhibit lung carcinogenesis in mice, Nat Genet, 29, 25, 10.1038/ng721

Rustgi, 2003, The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice, Cancer Res, 63, 2005

Sandgren, 2003, Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant kras in transgenic mice, Cancer Res, 63, 2016

Crowley, 2004, Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects, Cancer Cell, 5, 375, 10.1016/S1535-6108(04)00085-6

Hitt, 2003, Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse, Cancer Cell, 4, 437, 10.1016/S1535-6108(03)00309-X

You, 2003, LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer, Oncogene, 22, 1243, 10.1038/sj.onc.1206192

Balmain, 2008, Kras regulatory elements and exon 4A determine mutation specificity in lung cancer, Nat Genet, 40, 1240, 10.1038/ng.211

Jimeno, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368

Schmiegel, 1997, Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas, Cancer Res, 57, 3126

Yeo, 1997, Tumor-suppressive pathways in pancreatic carcinoma, Cancer Res, 57, 1731

DePinho, 1996, Role of the INK4a locus in tumor suppression and cell mortality, Cell, 85, 27, 10.1016/S0092-8674(00)81079-X

DePinho, 2003, Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma, Genes Dev, 17, 3112, 10.1101/gad.1158703

Sherr, 2003, Tumor suppression by Ink4a-Arf: progress and puzzles, Curr Opin Genet Dev, 13, 77, 10.1016/S0959-437X(02)00013-8

Lee, 1998, The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2′s inhibition of p53, Cell, 92, 713, 10.1016/S0092-8674(00)81400-2

Mahmood, 2006, Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse, Proc Natl Acad Sci U S A, 103, 5947, 10.1073/pnas.0601273103

DePinho, 2001, Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis, Nature, 413, 86, 10.1038/35092592

Hruban, 2003, Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray, Modern Pathology, 16, 902, 10.1097/01.MP.0000086072.56290.FB

Hruban, 2005, Precursors to invasive pancreatic cancer, Adv Anat Pathol, 12, 81, 10.1097/01.pap.0000155055.14238.25

Tuveson, 2005, Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice [see comment], Cancer Cell, 7, 469, 10.1016/j.ccr.2005.04.023

Brunton, Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer, Proc Natl Acad Sci U S A, 107, 246

Wiseman, 1994, Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation, Cancer Res, 54, 6257

Balmain, 1990, Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7, Cell, 61, 407, 10.1016/0092-8674(90)90523-H

Zhao, 2007, Growth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line, World J Gastroenterol, 13, 934, 10.3748/wjg.v13.i6.934

Brekken, 2005, Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy, Molecular Cancer Research: MCR, 3, 413, 10.1158/1541-7786.MCR-04-0206

Su, 2006, A novel mutation of STK11/LKB1 gene leads to the loss of cell growth inhibition in head and neck squamous cell carcinoma, Oncogene

Su, 2007, Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4, Cancer Lett, 245, 163, 10.1016/j.canlet.2006.01.003

Kern, 2006, Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays, Cancer Research, 66, 7920, 10.1158/0008-5472.CAN-06-0721

Iacobuzio-Donahue, 2007, Evaluation of GATA-4 and GATA-5 methylation profiles in human pancreatic cancers indicate promoter methylation patterns distinct from other human tumor types, Cancer Biol Ther, 6, 1546, 10.4161/cbt.6.10.4708

Hui, 2004, Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays, Nat Methods, 1, 109, 10.1038/nmeth718